U.S., Dec. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07280832) titled 'Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma' on Nov. 28.
Brief Summary: This is an open-label, multicenter Phase I/II clinical study conducted in participants with unresectable locally advanced or metastatic melanoma, aiming to evaluate the safety, tolerability, pharmacokinetic characteristics, and efficacy of JMT108 Injection in this population. The study consists of Phase I and Phase II (including Phase IIa and Phase IIb), where Phase I is the dose-escalation stage, Phase IIa is the dose-expansion stage, and Phase IIb is the cohort-expansion stage.
Study Start Date: Dec. 18
Stud...